文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

18F-氟胆碱PET/CT预测局限期前列腺癌根治性放疗反应的价值

Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-07-27

本研究回顾性分析50例2012至2017年间接受根治性放疗的局限期前列腺癌患者治疗前FCH PET/CT,随访至少3年。多因素分析显示,NDF患者前列腺内FCH各病灶SUVmax、SUVmean及两者之和均显著高于DF患者,TLCKA总和亦显著更高;多数PET指标及Gleason评分可预测3年随访后的生化复发。

要点

  • 前列腺内多灶性FCH摄取见于54%的患者,3年随访时74%为无病状态。
  • NDF患者前列腺内FCH病灶SUVmax、SUVmean及两者之和均显著高于DF患者。
  • NDF患者FCH病灶TLCKA总和显著高于DF患者(中位54.5 vs 29.4)。

核心结论

  • 较高的SUV值似乎预示多灶性前列腺内病灶接受根治性放疗的患者预后更差。

研究设计与样本

  • 单中心回顾性研究,纳入2012至2017年间接受根治性放疗且随访至少3年的50例局限期前列腺癌患者,分析其治疗前FCH PET/CT代谢参数。

主要发现

  • 27例(54%)患者前列腺内可见多灶性FCH摄取。
  • 3年随访时37例(74%)判定为无病(DF),13例(26%)为非无病(NDF)。
  • NDF患者前列腺内所有FCH病灶的SUVmax、SUVmean及两者之和均显著高于DF患者(均p < 0.005)。
  • NDF患者所有FCH病灶TLCKA总和显著高于DF患者(中位54.5 vs 29.4;p < 0.05)。
  • 单因素分析中,多数PET指标及Gleason评分可预测3年随访后的生化复发(均p < 0.05)。

关键数值与推荐

  • 根治性放疗总等效剂量为76-80 Gy,采用标准或大分割方案。
  • 无病(DF)定义为放疗后PSA较最低值升高<2 ng/mL;非无病(NDF)定义为升高>2 ng/mL。

临床怎么用

  • 治疗前FCH PET/CT所示前列腺内病灶SUV值及TLCKA总和可能有助于识别根治性放疗后生化复发风险较高的局限期前列腺癌患者。

局限性

  • 单中心回顾性设计,样本量50例,随访至少3年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to establish whether metabolic parameters obtainable from FCH PET/CT can predict long-term response to radical radiotherapy (rRT) in patients with localized prostate cancer (PCa). METHODS: Drawing on a single-center database, we retrospectively reviewed the pre-treatment FCH PET/CT scans of 50 patients who underwent rRT between 2012 and 2017. Patients were enrolled if they had a follow-up of at least 3 years after rRT. Various metabolic parameters were considered for each PET/CT, including FCH multifocality. rRT was administered to all patients for a total equivalent dose of 76-80 Gy, using a standard or hypofractionated schedule. Patients were classified as disease-free (DF) if their PSA levels after rRT rose by <2 ng/mL vis-à-vis their PSA nadir, or as not disease free (NDF) if their PSA levels rose by more than 2 ng/ml. RESULTS: A multifocal FCH uptake in the prostate gland was identified in 27 patients (54%). At 3-year follow-up, 37 patients (74%) were judged DF, and 13 (26%) were NDF. The SUVmax and SUVmean, and the sum of the two values in all FCH foci in the prostate gland were significantly higher for NDF patients than for DF patients (all p < 0.005). The sum of the TLCKA levels in all FCH foci was likewise significantly higher in patients who were NDF than in those found DF (median 54.5 vs. 29.4; p < 0.05). At univariate analysis, the most of PET-metrics and Gleason Score were predictors of biochemical relapse after 3-year follow-up (all p < 0.05). CONCLUSION: Higher SUVs seems predict a worse outcome for patients with multifocal intraprostatic lesions who are candidates for rRT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sepulcri M, Fusella M, Cuppari L, et al. Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer. Clin Transl Radiat Oncol. 2021. PMID: 34409175. doi:10.1016/j.ctro.2021.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。